Fibrodysplasia Ossificans Progressiva Medication

Updated: May 13, 2022
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD  more...
  • Print

Medication Summary

No effective medical therapy is known for fibrodysplasia ossificans progressiva (FOP). [46, 47] In a mouse model, ruxolitinib reduced phosphorylation of Stat3 and the development of heterotopic ossification [48] ; it has been suggested for use in humans. Novel therapies are being developed; clinical trials have been underway with palovarotene, REGN 2477, and rapamycin. [49]